Tuberculosis Immunity in Children
| Tracking Information | |
|---|---|
| First Received Date ICMJE | September 13, 2005 |
| Last Updated Date | April 24, 2008 |
| Start Date ICMJE | April 2005 |
| Primary Completion Date | Not Provided |
| Current Primary Outcome Measures ICMJE | Not Provided |
| Original Primary Outcome Measures ICMJE | Not Provided |
| Change History | Complete list of historical versions of study NCT00170638 on ClinicalTrials.gov Archive Site |
| Current Secondary Outcome Measures ICMJE | Not Provided |
| Original Secondary Outcome Measures ICMJE | Not Provided |
| Current Other Outcome Measures ICMJE | Not Provided |
| Original Other Outcome Measures ICMJE | Not Provided |
| Descriptive Information | |
| Brief Title ICMJE | Tuberculosis Immunity in Children |
| Official Title ICMJE | Tuberculosis Immunity in Children |
| Brief Summary | The purpose of this study is to gain a better understanding of how immunity to tuberculosis (TB) is maintained in children. When children get tuberculosis, it is more likely to spread to other parts of the body than when adults get it. This study will compare the blood cells that fight TB in children to the blood cells that fight TB in adults. Children enrolled in this study will have blood drawn on 1 or 2 occasions. Adult participants will be leukapheresed, a process in which blood passes through a machine collecting specific blood cells and returning the remaining blood to the body. An estimated 260 subjects will be enrolled in this study. |
| Detailed Description | Tuberculosis (TB) is the number one cause of infectious morbidity and mortality worldwide accounting for 8 million cases and 3 million deaths annually. The impact of TB on children is particularly devastating in that children are more likely than adults to develop active TB following exposure to the bacterium, M. tuberculosis (Mtb) and once infected, children are much more likely than adults to develop disseminated disease, including miliary disease, bone and joint disease, and meningitis. These clinical differences likely reflect fundamental differences of the immune system of children and adults. The first specific aim of this study is to determine if severity of disease following Mtb infection in young children is associated with TH2-type immunity; and conversely, if absence of disease following Mtb infection is associated with TH1-type immunity by comparison of the magnitude and phenotype of Mtb-specific T cell responses in children less than or equal to 10 years old with: disseminated TB including miliary disease and meningitis; localized disease as defined by disease contained in the thoracic cavity (pulmonary, pleural, and cardiac), extrapulmonary lymph nodes (lymphadenitis), gastrointestinal tract, or bone (osteomyelitis); and latent Mtb infection (LTBI) defined as individuals with a positive Tuberculin Skin Test (TST) and without radiographic or clinical evidence of active tuberculosis. The second specific aim of this study is to determine if immunologic immaturity is associated with the development of TH2-type immunity following Mtb infection, and conversely if immunologic maturity is associated with the development of TH1-type immunity following Mtb infection by characterizing the magnitude and phenotype of Mtb-specific T cell responses in individuals with: localized disease; comparing 0-1 year olds, 2-4 year olds, 5-10 year olds, and adults; and LTBI; comparing 0-1 year olds, 2-4 year olds, 5-10 year olds, and adults. The data obtained from the present study may contribute to an improved understanding of TB immunity in children, which in turn may help in the development of a more effective TB vaccine for infants and young children. The number of participants is estimated to be 260 subjects to be enrolled over the course of 5 years. |
| Study Type ICMJE | Observational |
| Study Design ICMJE | Time Perspective: Prospective |
| Target Follow-Up Duration | Not Provided |
| Biospecimen | Not Provided |
| Sampling Method | Not Provided |
| Study Population | Not Provided |
| Condition ICMJE | Tuberculosis |
| Intervention ICMJE | Not Provided |
| Study Group/Cohort (s) | Not Provided |
| Publications * | Not Provided |
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|
| Recruitment Information | |
| Recruitment Status ICMJE | Completed |
| Enrollment ICMJE | 260 |
| Completion Date | April 2010 |
| Primary Completion Date | Not Provided |
| Eligibility Criteria ICMJE | Inclusion Criteria: Children:
Adults:
Exclusion Criteria:
|
| Gender | Both |
| Ages | Not Provided |
| Accepts Healthy Volunteers | No |
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects |
| Location Countries ICMJE | United States |
| Administrative Information | |
| NCT Number ICMJE | NCT00170638 |
| Other Study ID Numbers ICMJE | 03-202 |
| Has Data Monitoring Committee | Not Provided |
| Responsible Party | Not Provided |
| Study Sponsor ICMJE | National Institute of Allergy and Infectious Diseases (NIAID) |
| Collaborators ICMJE | Not Provided |
| Investigators ICMJE | Not Provided |
| Information Provided By | National Institute of Allergy and Infectious Diseases (NIAID) |
| Verification Date | January 2008 |
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|